Imatinib mesylate is a tyrosine kinase inhibitor used widely as the first-line treatment for chronic myeloid leukaemia (CML). The side-effect profile of this drug includes fluid retention, muscle cramps, diarrhoea, myelosuppression and skin rashes. Of these, rashes of the type maculo-papular eruptions and oedema developed most commonly. The cutaneous adverse reactions other than maculo-papular eruptions are rare with imatinib. Severe and life-threatening cutaneous reactions can occur in 5% cases. Here, the author reports a case of newly diagnosed CML that developed Steven-Johnsons syndrome due to imatinib therapy. Patient responded and discharged successfully on withdrawal of the culminating drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604560 | PMC |
| http://dx.doi.org/10.1136/bcr-2012-007926 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Cancers (Basel)
December 2024
Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Doha P.O. Box 3050, Qatar.
Background: Renal adverse drug reactions (ADRs) associated with tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) are relatively rare, and there is currently no standardized protocol for their management. Therefore, this study aimed to summarize renal ADRs related to TKIs use in CML and propose an evidence-based approach to monitor and manage these ADRs.
Methods: A systematic literature review was performed to identify renal ADRs associated with TKIs in CML.
Case Report: Loeffler endocarditis as a cause of left ventricular thrombosis in young women: a case study and literature review.
Front Cardiovasc Med
December 2024
Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University, Shandong First Medical University, Shandong, China.
It is unusual for young patients without any underlying diseases to experience sudden cerebral infarction and heart failure. Here, we report a rare case of a 28-year-old female patient who presented with chest tightness and dizziness. Left ventricular thrombus formation and cardiac insufficiency were evident on echocardiogram, while multiple acute or subacute cerebral infarctions were visible on brain magnetic resonance imaging.
View Article and Find Full Text PDFComplex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/ Rearrangement, Mutation, and Transient Chimera.
Cancer Genomics Proteomics
December 2024
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;
Background/aim: Myelodysplastic syndromes (MDSs) are clonal bone marrow disorders characterized by ineffective hematopoiesis. They are classified based on morphology and genetic alterations, with SF3B1 variants linked to favorable prognosis and MECOM rearrangements associated with poor outcomes. The combined effects of these alterations remain unclear.
View Article and Find Full Text PDFPathologic diagnosis and molecular features of gastrointestinal stromal tumors: a mini-review.
Front Oncol
November 2024
Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Article Synopsis
- * About 80% of GISTs have mutations in KIT or PDGFRA that affect how they behave and respond to treatment; a special type called SDH-deficient GISTs is linked to certain genetic syndromes and presents different challenges.
- * The primary treatment involves surgery and the drug imatinib for advanced cases, but resistance to treatment is a major issue, particularly in kids and wildtype GISTs, highlighting the need for better therapies and personalized treatment approaches.
[Research progress of iron metabolism and ferroptosis in myeloid neoplasms].
Zhejiang Da Xue Xue Bao Yi Xue Ban
December 2024
Institute of Translational Medicine, Zhejiang University, Hangzhou 310058, China.
Article Synopsis
- Dysregulation of iron metabolism is linked to various myeloid neoplasms, affecting prognosis, especially in conditions like acute myeloid leukemia and myelodysplastic syndrome.
- Myeloproliferative neoplasms often show both iron deficiency and elevated red blood cell levels, which can be managed by targeting the protein hepcidin.
- Research suggests that ferroptosis, a form of cell death, could be a promising therapeutic approach to treat these neoplasms by reversing drug resistance and promoting anti-tumor effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!